Biomedic Menoflavone Extra strength
Natural health product licensed in Canada
- Other names
- BIOMEDIC MÉNOFLAVONE EXTRA FORT, Dr Nutrition 360 Menoflavone, MapleLife Nutrition Menoflavone
- Licence holder
- Nutralab Canada Corp.
- NPN or DIN-HM
- 80089334
- Status
- Active licence
- Licence date
- 26 November 2018
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Extrait d'isoflavones de trèfle rouge Source : Trifolium pratense - sommité (herbe) | 200 milligramme | Not calculated |
Non-medicinal ingredients
Glycolate d'amidon sodique, Poly(éthylène glycol), Talc, Phosphate dicalcique, Poly(alcool vinylique), Stéarate de magnésium, Oxyde de fer noir, Hydroxypropyl méthylcellulose, Oxyde de fer (Fe2O3), Cellulose microcristalline, Dioxyde de silicium, Oxyde de fer jaune, Acide stéarique
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Femmes ménopausées et en postménopause | Not specified | 1 Comprimé | 1 Tous les jours |
Uses authorised in Canada
Menopausal and postmenopausal women: May reduce severe and frequent menopausal symptoms (such as hot flashes/flushes and/or night sweats). Postmenopausal women: Helps to attenuate/reduce bone mineral density (BMD) loss in post-menopausal women when used in conjunction with adequate amounts of calcium and vitamin D.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
If you currently have or previously had breast cancer or if you have a predisposition to breast cancer, as indicated by an abnormal mammogram and/or biopsy, or if you have a family member with breast cancer, do not use this product.
- Précautions et mises en garde
If you have a history of hormonal or gynecological disease including ovarian cancer, endometriosis and/or uterine fibroids, consult a health care practitioner prior to use. Ensure that you are up-to-date on appointed clinical tests such as mammograms and endometrial ultrasounds or biopsies before using this product. If you experience breast pain, discomfort, soreness and/or tenderness, abnormal uterine bleeding including spotting and/or recurrence of menstruation in postmenopausal women, discontinue use and consult a health care practitioner. If you are taking hormone replacement therapy, consult a health care practitioner prior to use. Hot flashes and/or night sweats: If symptoms worsen, consult a health care practitioner. Pre-menopausal Women: If you are pregnant or breastfeeding, consult a healthcare practitioner prior to use.
Source
Official Health Canada record, licence 80089334
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.